MarketCap
Facebook
X
Telegram
China SXT Pharmaceuticals Balance Sheet 2026-2011 | SXTC
Brief overview of China SXT Pharmaceuticals's financial position
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets fell from $34.5 million to $21.7 million. This may reflect either deliberate optimization or a reduction in business scale.
Assets outpaced liabilities, -37.3% versus -66.5%. Dependence on external funding declined.
Equity funds 71.3% of assets versus 46.2% initially. This creates a conservative balance sheet structure.
The balance sheet holds more cash than interest-bearing debt; net debt is -$18 million, indicating minimal leverage.
The cash reserve occupies 83.5% of the balance sheet, previously 38.7%. It is one marker of short-term resilience.
The accumulated result is -$28 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
The indicators point to a strong balance sheet position for China SXT Pharmaceuticals: funding is balanced and liability risks appear controlled.
Annual Balance Sheet China SXT Pharmaceuticals
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-27.5 M | -18 M | -11.9 M | -17.2 M | - | -13.4 M | -563 K | -8.83 M | -175 K | 237 K | - | - | - | - | - | - |
Long Term Debt |
644 K | 96.3 K | 117 K | 118 K | - | 6.29 K | 36.5 K | 41.7 K | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | 8.78 K | 21.3 K | 58.1 K | 11.4 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
698 K | 212 K | 295 K | 366 K | - | 6.29 K | 36.5 K | 41.7 K | - | - | - | - | - | - | - | - |
Total Current Liabilities |
4.35 M | 6.01 M | 8.9 M | 14.5 M | 17.1 M | 18.6 M | 12.3 M | 6.32 M | - | - | - | - | - | - | - | - |
Total Liabilities |
5.05 M | 6.22 M | 9.2 M | 14.9 M | 17.1 M | 18.6 M | 12.3 M | 6.36 M | 4.37 M | 3.58 M | - | - | - | - | - | - |
Deferred Revenue |
104 K | 58.6 K | 188 K | 166 K | - | - | - | - | - | 586 K | - | - | - | - | - | - |
Retained Earnings |
-34.2 M | -28 M | -24.7 M | -21.6 M | -15.7 M | -9.95 M | -7.2 M | 3.08 M | 1.54 M | 357 K | - | - | - | - | - | - |
Total Assets |
34.8 M | 21.7 M | 23.1 M | 29.6 M | 33.5 M | 34.5 M | 21.7 M | 17.5 M | 7.66 M | 5.43 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
28.2 M | 18.1 M | 12.1 M | 17.4 M | 77.4 K | 13.4 M | 7.29 M | 9.13 M | 658 K | 65.6 K | - | - | - | - | - | - |
Book Value |
29.7 M | 15.4 M | 13.9 M | 14.7 M | 16.4 M | 16 M | 9.4 M | 11.1 M | 3.29 M | 1.85 M | - | - | - | - | - | - |
Total Shareholders Equity |
29.7 M | 15.4 M | 13.9 M | 14.7 M | 16.1 M | 16 M | 9.4 M | 11.1 M | 3.29 M | 1.85 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet China SXT Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
73.1 K | 644 K | 115 K | 96.3 K | 107 K | 117 K | - | 118 K | - | - | - | - | - | - | - | 6.29 K | - | 15.2 K | - | 36.5 K | - | 55.1 K | - | 41.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
158 K | 698 K | 298 K | 212 K | 312 K | 295 K | - | 366 K | - | - | - | - | - | - | - | 6.29 K | - | 15.2 K | - | 36.5 K | - | 873 K | - | 41.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.12 M | 5.05 M | 16 M | 6.22 M | 9.51 M | 9.2 M | 7.29 M | 14.9 M | - | - | - | 17.1 M | - | 8.88 M | - | 18.6 M | - | 5.52 M | - | 12.3 M | - | 11.6 M | - | 6.36 M | - | - | - | 4.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
65.1 K | 104 K | 190 K | 58.6 K | - | 188 K | - | 166 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-34.4 M | -34.2 M | -25.5 M | -28 M | -31.3 M | -24.7 M | -17.2 M | -21.6 M | - | - | - | -15.7 M | - | -13 M | - | -9.95 M | - | -5.82 M | - | -7.2 M | - | 736 K | - | 3.08 M | - | - | - | 1.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
26.4 M | 34.8 M | 31 M | 21.7 M | 14.6 M | 23.1 M | 22.2 M | 29.6 M | - | - | - | 33.5 M | - | 22.7 M | - | 34.5 M | - | 24 M | - | 21.7 M | - | 23 M | - | 17.5 M | - | - | - | 7.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
21.2 M | 28.2 M | 18.5 M | 18.1 M | 11.5 M | 12.1 M | 2.98 M | 17.4 M | - | - | - | 15.5 M | - | 31.3 K | - | 13.3 M | - | 10.4 M | - | 7.29 M | - | 8.25 M | - | 9.29 M | - | 384 K | - | 658 K | - | - | - | 65.6 K | - | - | - | 11.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
20.2 M | 29.7 M | 15 M | 15.4 M | 5.08 M | 13.9 M | 14.9 M | 14.7 M | - | - | - | 16.4 M | - | 13.8 M | - | 16 M | - | 18.5 M | - | 9.4 M | - | 11.4 M | - | 11.1 M | - | - | - | 3.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
20.2 M | 29.7 M | 15 M | 15.4 M | 5.08 M | 13.9 M | 14.9 M | 14.7 M | - | - | - | 16.4 M | - | 13.8 M | - | 16 M | - | 18.5 M | - | 9.4 M | - | 11.4 M | - | 11.1 M | - | 4.6 M | - | 3.29 M | - | - | - | 1.85 M | - | - | - | 743 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of China SXT Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
